SEGMENTS INFORMATION - Segment Revenue, Significant Segment Expenses and Segment Operating EBITDA (Details) - USD ($) $ in Millions	3 Months Ended
Mar. 31, 2026	Mar. 31, 2025
Segment Reporting Information [Line Items]
Equity in earnings (loss) of nonconsolidated affiliates	$ (1)	$ (15)
Healthcare & Water Technologies
Segment Reporting Information [Line Items]
Segment net sales	806	763
Cost of sales	496	478
Selling, general and administrative expenses	93	85
Research and development expenses	22	20
Amortization of intangibles & other segment items	43	49
Equity in earnings (loss) of nonconsolidated affiliates	1	0
Depreciation and amortization	91	92
Segment operating EBITDA	244	223
Diversified Industrials
Segment Reporting Information [Line Items]
Segment net sales	875	849
Cost of sales	571	568
Selling, general and administrative expenses	116	106
Research and development expenses	28	23
Amortization of intangibles & other segment items	24	26
Equity in earnings (loss) of nonconsolidated affiliates	(1)	0
Depreciation and amortization	65	59
Segment operating EBITDA	$ 200	$ 185

Amount of income (loss) for proportionate share of equity method investee's income (loss).

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481664/323-10-45-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(12))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(f))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Name:	us-gaap_IncomeLossFromEquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration